Ambrx Granted Orphan Drug Designation for ARX788 for the Treatment of Gastric Cancer
Ambrx was granted orphan drug designation by the FDA for its drug ARX788, which is in clinical trials to treat HER2-positive gastric... Read More
Zolbetuximab Plus EOX vs EOX Alone for First-Line Treatment of Advanced CLDN18.2-Positive Gastric and Gastro-Oesophageal Adenocarcinoma
In a phase 2 trial in advanced gastric cancer with high expression of CLDN18.2, adding Ganymed Pharmaceuticals’experimental drug zolbetuximab to chemotherapy improved... Read More
Safety and feasibility of minimally invasive surgical interventions for esophageal and gastric cancer in the acute setting
Dutch researchers found in a recent study that minimally invasive surgery in gastric cancer is safe, feasible and offers comparable short-term outcomes... Read More
New Published Research from the Gastric Cancer Registry Team
Our Gastric Cancer Registry project at Stanford is leading to important research and new discoveries. A recently published study used joint single... Read More
Quality of Life Maintained With Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
A study presented at ASCO GI found that the immunotherapy drug Opdivo given to gastric cancer patients after surgery lowers relapse risk... Read More
Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma
Adding Herceptin to chemotherapy improved outcomes for patients with HER2-positive advanced gastric cancer in a clinical trial.
Chatter Between Cell Populations Drives Progression of Gastrointestinal Tumors
Researchers at UCSD discovered that cancer-associated fibroblasts within gastrointestinal stromal tumors (GISTs) communicate with GIST cells to drive tumor growth.
Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer
Integrating interdisciplinary supportive care into the treatment of metastatic gastric cancer enhances survival benefits, a recent study published in the Journal of... Read More
Dynamic, personalized treatment approach may improve outcomes in gastroesophageal cancers
A University of Chicago study found that when treatments are customized for gastric cancer patients based on the genetic characteristics of their... Read More
The Gut Microbiome Offers Clues to Immunotherapy Efficacy in Advanced Gastric Cancer
Japanese researchers found a link between the gut microbiome and a positive response to the immunotherapy drug Opdivo in patients with gastric... Read More